Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:4914
Name esophagus adenocarcinoma
Definition An esophageal carcinoma that derives_from epithelial cells of glandular origin.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer esophageal cancer esophageal carcinoma esophagus adenocarcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
ERBB2 amp Lapatinib esophagus adenocarcinoma no benefit detail...
Unknown unknown IMR-1 esophagus adenocarcinoma not applicable detail...
ERBB2 amp FGFR2 amp AZD4547 + Lapatinib esophagus adenocarcinoma sensitive detail...
ERBB2 over exp Trastuzumab esophagus adenocarcinoma sensitive detail...
Unknown unknown Nintedanib esophagus adenocarcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01196390 Phase III Carboplatin + Paclitaxel + Trastuzumab Carboplatin + Paclitaxel Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Active, not recruiting USA 0
NCT01307956 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer Terminated USA 0
NCT01490749 Phase I Carboplatin + Cetuximab + Everolimus + Paclitaxel Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer Completed USA 0
NCT01526473 Phase I AVX901 A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 Completed USA 0
NCT01747551 Phase II Aflibercept Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer Completed USA 0
NCT01774851 Phase II MM-111 + Paclitaxel + Trastuzumab Paclitaxel + Trastuzumab A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Terminated USA 0
NCT01913639 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Regorafenib FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer Completed USA 0
NCT02013154 Phase I DKN-01 + Paclitaxel A Study of DKN-01 in Combination With Paclitaxel Active, not recruiting USA 0
NCT02016534 Phase II AMG 337 Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors Terminated USA | CAN 16
NCT02024607 Phase Ib/II Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Completed USA | CAN 0
NCT02138929 Phase I Everolimus + Sonidegib LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma Completed USA 0
NCT02234180 Phase II Regorafenib Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy Terminated USA 0
NCT02234596 Phase II Nintedanib Nintedanib in Patients With Advanced Esophagogastric Cancer Completed USA 0
NCT02241720 Phase II Regorafenib Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers Terminated USA 0
NCT02283359 Phase I Irinotecan + Selinexor Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus Terminated USA 0
NCT02317991 Phase II Nab-paclitaxel + Ramucirumab Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer Active, not recruiting USA 0
NCT02389751 Phase I Carboplatin Paclitaxel Ganetespib A Study of Ganetespib in Combination With Chemoradiation Completed USA 0
NCT02404441 Phase Ib/II Spartalizumab Phase I/II Study of PDR001 in Patients With Advanced Malignancies Completed USA | CAN 12
NCT02460224 Phase Ib/II LAG525 Spartalizumab Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Completed USA | CAN 10
NCT02530437 Phase Ib/II Taladegib Carboplatin + Paclitaxel A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction Active, not recruiting USA 0
NCT02559687 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) Active, not recruiting 0
NCT02564263 Phase III Pembrolizumab Docetaxel + Irinotecan + Paclitaxel Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Active, not recruiting 0
NCT02638909 Phase II Ceritinib Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies Terminated USA 0
NCT02639065 Phase II Durvalumab A Study of Durvalumab (MEDI4736) in Esophageal Cancer Active, not recruiting USA 0
NCT02642809 Phase I Pembrolizumab Pembrolizumab With Locally Delivered Radiation Therapy for the Initial Treatment of Metastatic Esophageal Cancers Active, not recruiting USA 0
NCT02954536 Phase II Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer Active, not recruiting USA 0
NCT02962063 Phase Ib/II Carboplatin + Durvalumab + Paclitaxel Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer Recruiting USA 0
NCT02971956 Phase II Pembrolizumab A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer Active, not recruiting USA 0
NCT02998268 Phase II Pembrolizumab Carboplatin + Paclitaxel Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma Recruiting USA 0
NCT03064490 Phase II Carboplatin + Paclitaxel + Pembrolizumab Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED) Recruiting USA 0
NCT03122548 Phase II CRS-207 + Pembrolizumab Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers Terminated USA 0
NCT03132922 Phase I ADP-A2M4 cells MAGE-A4c1032T for Multi-Tumor Recruiting USA | CAN 0
NCT03165994 Phase II APX005M + Carboplatin + Paclitaxel APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers Recruiting USA 0
NCT03189719 Phase III Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Pembrolizumab First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590) Active, not recruiting USA | CAN 24
NCT03193918 Phase I Crenolanib + Paclitaxel + Ramucirumab Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma Completed USA 0
NCT03196232 Phase II Epacadostat + Pembrolizumab Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer Completed USA 0
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) Recruiting USA 0
NCT03365791 Phase II LAG525 Spartalizumab PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Completed USA 0
NCT03604991 Phase II Carboplatin + Paclitaxel Nivolumab Carboplatin + Nivolumab + Paclitaxel Ipilimumab + Nivolumab Carboplatin, Paclitaxel and Radiation Therapy With or Without Nivolumab and Ipilimumab in Treating Participants With Esophageal and Gastroesophageal Junction Adenocarcinoma Recruiting USA 0
NCT03610711 Phase Ib/II Nivolumab + Relatlimab Nivolumab REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (REACTION) Recruiting USA 0
NCT03694249 Phase II Ifetroban sodium Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence Recruiting USA 0
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Recruiting USA 5
NCT03783936 Phase II Avelumab + Trastuzumab Avelumab + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas Active, not recruiting USA 0
NCT03784326 Phase I Atezolizumab + Fluorouracil + Oxaliplatin Atezolizumab, Oxaliplatin, and Fluorouracil in Treating Patients With Esophageal or Gastroesophageal Cancer Recruiting USA 0
NCT03840967 Phase II Niraparib A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma Recruiting USA 0
NCT03997448 Phase II Abemaciclib + Pembrolizumab Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149 Active, not recruiting USA 0
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Recruiting USA 1
NCT04089904 Phase II Pembrolizumab Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma Recruiting USA 0
NCT04111172 Phase II Ad5.F35-hGCC-PADRE Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies Recruiting USA 0
NCT04137289 Phase I BI 905711 A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers Recruiting USA 3
NCT04152018 Phase I PF-06801591 + PF-06940434 PF-06940434 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Recruiting USA 0
NCT04171141 Phase I PF-07062119 PF-07062119 + unspecified PD-1 antibody PF-07062119 + unspecified VEGF antibody Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. Recruiting USA 1
NCT04210115 Phase III Cisplatin + Fluorouracil + Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Cisplatin + Fluorouracil Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) Recruiting USA | CAN 23
NCT04391049 Phase I Carboplatin + OBP-301 + Paclitaxel Testing the Addition of the Anti-cancer Viral Therapy Telomelysin to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery Recruiting USA 0
NCT04430738 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers Recruiting USA 0
NCT04460937 Phase I Adavosertib Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers Recruiting USA 0
NCT04510285 Phase II Pembrolizumab + Trastuzumab Trastuzumab Study of Pembrolizumab Plus Trastuzumab or Trastuzumab Alone After Surgery in Patients With Esophagogastric Tumors Recruiting USA 0
NCT04594811 Phase II Nivolumab Nivolumab + NT-I7 NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma Recruiting USA 0
NCT04757363 Phase II Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + Regorafenib A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer Recruiting USA 0